Researchers at the Swedish medical university Karolinska Institutet have discovered a mechanism that controls the brain's ability to create lasting memories. In experiments on genetically manipulated mice, they were able to switch on and off the animals' ability to form lasting memories by adding a substance to their drinking water. The findings, which are published in the scientific journal PNAS, are of potential significance to the future treatment of Alzheimer's and stroke. [More]

NovaDel Pharma Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715, entitled “Buccal, Polar and Non-polar Spray Containing Zolpidem,” which covers a method of treating insomnia by administering zolpidem to humans utilizing NovaMist™ Oral Spray spray technology. [More]

ExonHit Therapeutics yesterday presented clinical data on the validation set “Alzheimer patients versus healthy controls” for AclarusDx™ (formerly EHT Dx21), its blood-based diagnostic test for the detection of Alzheimer’s disease (AD), at the 2nd Conference of Clinical Trials on Alzheimer’s Disease (CTAD) in Las Vegas, USA. [More]

Top-line Phase IIa clinical data released today demonstrate that EHT 0202, ExonHit’s lead candidate for the treatment of Alzheimer’s disease, is safe and generally well tolerated in patients and that it could potentially enhance cognition in Alzheimer’s disease patients. [More]

Valeant Pharmaceuticals International today announced preliminary results from its Phase IIa proof-of-concept clinical trial of retigabine for the treatment of pain associated with postherpetic neuralgia (PHN), a painful and common complication of shingles. [More]

A new study shows that nervous system integrity and axonal properties may play a key role in prion diseases. The findings, from researchers at the Rudolf Virchow Center and the Institute of Virology of the University of W-rzburg, expand our understanding of the development of prion disease and suggest novel targets for therapeutic and diagnostic approaches in its early stages. [More]

Say goodbye to Italian-Americans and German-Americans and say hello to Vietnamese-Americans, Salvadoran-Americans and a bunch of other hyphenated Americans. [More]

It's estimated that more than a half million kids in the U.S. go to the hospital each year with a concussion. [More]

You know the feeling. You make a decision you're certain is merely a "lucky guess." [More]

According to the latest figures from the Agency for Healthcare Research and Quality (AHRQ) in the United States, one in five hospital admissions are for patients with mental disorders. [More]

Scientists at the University of Liverpool have discovered dramatic differences in the memory performance of patients with damage to the hippocampus, an area of the human brain key to memory. [More]

People who survived the Indian Ocean tsunami or lost loved ones in the disaster went through a complex process of trauma and grief, according to research published in the latest Journal of Advanced Nursing. [More]

A recent CDC report on HIV/AIDS in the U.S. -- which found that about 56,000 new HIV infections occur in the U.S. each year -- "should serve as a wake-up call from the AIDS amnesia surrounding the domestic epidemic in recent years," Susan Blumenthal, senior policy and medical adviser at the Foundation for AIDS Research, and Melissa Shive, a former research assistant at amfAR and medical student at the University of California-San Francisco, write in a Washington Times opinion piece. [More]

Often, a gentle hand on your shoulder when you're upset is all it takes to ease your mind and calm your nerves. Now, University of Cincinnati (UC) researchers are looking at a similar occurrence by pairing a complementary therapy known as Healing Touch with mild sedation to see if the technique truly calms patients undergoing minor procedures. [More]

Mylan Inc. has announced that its subsidiary, Genpharm ULC, has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Zaleplon Capsules, 5 mg and 10 mg. [More]